BTG Pactual Asset Management US’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

BTG Pactual Asset Management US’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$913K	Sell	7,146 -136	-2%	-$17K	0.08%	149
2025 Q4	$888K	Sell	7,282 -8,508	-54%	-$976K	0.09%	110
2025 Q3	$1.31M	Buy	15,790 +8,272	+110%	+$745K	0.06%	88
2025 Q2	$623K	Sell	7,518 -100	-1%	-$7.98K	0.07%	130
2025 Q1	$618K	Sell	7,618 -1,879	-20%	-$168K	0.07%	156
2024 Q4	$939K	Sell	9,497 -500	-5%	-$48.4K	0.1%	155
2024 Q3	$988K	Buy	+9,997	New	+$982K	0.08%	161

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BTG Pactual Asset Management US's XBI Position: Q1 2026 in Review

BTG Pactual Asset Management US reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 1.9% in Q1 2026, selling an estimated $17K and leaving 7,146 shares worth $913K. The position accounts for 0.08% of the portfolio, ranked #149.

BTG Pactual Asset Management US first reported a position in XBI in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.31M in Q3 2025. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

BTG Pactual Asset Management US held 7,146 shares of State Street SPDR S&P Biotech ETF worth $913K as of Q1 2026.
BTG Pactual Asset Management US sold 136 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $17K.
State Street SPDR S&P Biotech ETF made up 0.08% of BTG Pactual Asset Management US's portfolio in Q1 2026, its #149 holding.
BTG Pactual Asset Management US first reported a position in State Street SPDR S&P Biotech ETF in Q3 2024 and has held it in 7 quarters since.
BTG Pactual Asset Management US's State Street SPDR S&P Biotech ETF position peaked at $1.31M in Q3 2025.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on BTG Pactual Asset Management US's 13F filing for Q1 2026, filed 14 May 2026.